08
May
2008
In a recent interview with the Star-Ledger, New Jersey-based Celgene (NASDAQ: CELG) Chief Executive Officer Sol J. Barer, Ph.D. provided some insight as to the integration plans for Pharmion products and intellectual capital. Following is a portion of that Q&A. Q: Celgene already was expanding its presence abroad. What does adding Pharmion do for you [...]
10
Mar
2008
You know a deal is done when one goes to the Pharmion.com website and the Celgene (NASDAQ: CELG) site pulls up. Last Thursday Pharmion shareholders approved the acquisition and by Friday it was signed, sealed and delivered…$2.9B later or $25 in cash plus 0.8367 shares of Celgene for each share of Pharmion. Congratulations to both [...]
15
Feb
2008
News continues to pour out of Pharmion (NASDAQ: PHRM) of late and believe it or not today’s tidbit is not related to the Celgene (NASDAQ: CELG) acquisition, rather it is focused on the MGCD0103 product for the treatment of acute Myelogenous Leukemia with development and commercialization partner MethylGene (TSX: MYG). This week proved very encouraging [...]
08
Feb
2008
Just when you think the $2.9B Celgene (NASDAQ: CELG) acquisition of Pharmion (NASDAQ: PHRM) is all but a done deal enter one Steven A. Cohen of S|A|C Capital Advisors, a private asset management firm who with its sub CR Intrinsic Investments, hold in aggregate approximately 3 million shares of Pharmion and thus near 10% of [...]
30
Jan
2008
A very interesting few days for Pharmion (NASDAQ: PHRM) and Celgene (NASDAQ: CELG) and how they are faring in their product approval efforts in Europe. The European Medicines Agency issued a positive opinion to recommend approval of Pharmion’s Thalidomide® for use in combination with melphalan and prednisone as first line treatment for patients with untreated [...]
05
Jan
2008
The $2.9B acquisition of Pharmion (NASDAQ: PHRM) by Celgene (NASDAQ: CELG) took another step towards closing the deal as the obligatory waiting period as required by the FTC and the Antitrust Improvements Act of 1976 expired, perhaps now clearing the way for smooth sailing to inking the deal in under 120 days. This is good. [...]
18
Nov
2007
OK…it was just a few weeks ago when I highlighted Celgene’s (NASDAQ: CELG) concentrated activity in Colorado bio, take a look (here). The Colorado bioscape has proved to be an incredibly active market for big pharma in the last year, accounting for nearly a whopping $7 billion in transactions! Just to quickly review these deals [...]
16
Oct
2007
Pharmion (Nasdaq: PHRM) and MethylGene (TSX: MYG) announced initiation of a Phase I trial for MGCD0103, a isotype-selective histone deacetylase inhibitor in combination with Taxotere from Sanofi Aventis (NYSE: SNY) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer. Key [...]
27
Sep
2007
Celgene Makes Ya Go Hmmm…
Posted in CO Private: GlobeImmune, CO Pub Rel: Celgene, CO Public: Array, CO Public: Pharmion
Just what I think to be an interesting observation…that is how deep New Jersey-based Celgene (NASDAQ: CELG) has penetrated into the Colorado bio-scape. The connection appears to have initiated back in 2001 on a licensing deal with Pharmion (NASDAQ: PHRM) for Thalomid® (BTW…take a listen to Pharmion’s UBS Global Life Sciences Conference presentation from today [...]
16
Nov
2006
Pharmion: Bucks the Trend
Posted in CO Public: Pharmion
After a fury of CO life science companies that have recently been acquired (e.g. Myogen/Gilead, RxKinetix/Endo and Sirna/Merck), Pharmion, Inc. (NASDAQ: PHRM) has reversed this local trend and gone out and purchased Cabrellis (privately held, San Diego, CA) for $55M with an additional $45M pending. Two additional payments of $12.5M are expected upon approval of [...]
Life Science Deal Flow PARTNERS
-
